Rafael Holdings continues Phase 3 trial after DMC approval
An independent Data Monitoring Committee recommended proceeding with the Phase 3 study for Trappsol Cyclo. The therapy addresses a significant unmet medical need projected at over $920 million by 2031.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
GET FREE KEY — 10,000 calls/day